GlassScriptPhysician profile
Stephen Matthew Burke
NPI 1851392492
$1,826.40
in general payments reported to CMS, 2019-2025
20 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $344 · 2021: $324 · 2022: $153 · 2023: $333 · 2024: $217 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.57 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $437.54 | 2019-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $316.33 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $266.72 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $204.61 | 2021-2025 | Ubrelvy, Qulipta |
| Allergan, INC. | $161.03 | 2020 | |
| Novartis Pharmaceuticals Corporation | $77.56 | 2023-2025 | |
| Lilly USA, LLC | $62.26 | 2024-2025 | Jardiance |
| Pfizer INC. | $45.45 | 2020 | |
| Amgen INC. | $39.78 | 2021-2023 | Otezla, Repatha |
| Abbott Laboratories | $34.81 | 2019-2025 | Eterna |
| Boston Scientific Corporation | $31.79 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $23.00 | 2020-2021 | |
| Dexcom, INC. | $22.88 | 2023 | Dexcom G6 Transmitter |
| Philips North America LLC | $19.67 | 2024 | (Ck7) Extended Holter |
| Sumitomo Pharma America, INC. | $18.30 | 2023 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $14.24 | 2025 | Natroba, Spinosad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.35 | 2022 | |
| Corium, LLC | $13.26 | 2023 | Adlarity |
| Nevro Corp. | $12.40 | 2022 | |
| Merck Sharp & Dohme LLC | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.